Online inquiry

IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1599MR)

This product GTTS-WQ1599MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GDF11 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005811.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10220
UniProt ID O95390
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1599MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8435MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ11889MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ11117MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ841MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ7384MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ4107MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ9132MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ2366MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW